Research programme: ophthalmic therapies - Bayer HealthCare/Johns Hopkins University
Latest Information Update: 14 Jul 2015
At a glance
- Originator Bayer HealthCare; Johns Hopkins University
- Class Eye disorder therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Retinal disorders
Most Recent Events
- 16 Jun 2015 Early research in Retinal disorders in USA and Germany (Ophthalmic)